PwC IPO Head Discusses Market Selectivity, AI Value And 2027 Outlook
PricewaterhouseCoopers IPO leader Mike Bellin discusses the current state of the U.S. initial public offering market, highlighting investor selectivity, AI company valuation, biotech revival, and the outlook for 2027.

The United States initial public offering market has rebounded, though the recovery remains uneven. Enterprises attempting to go public encounter investors who are intensely focused on durable revenue, profitability, and reasonable valuations, while ongoing uncertainty has led some issuers to postpone their planned market debuts.
Mike Bellin, a partner and U.S. IPO services leader at PricewaterhouseCoopers, observes a market that stays open for businesses possessing the appropriate scale, financial metrics, and preparation.
During a recent discussion with Crunchbase News, Bellin analyzed the cooling of IPO momentum, the methods public investors are using to assess artificial intelligence enterprises, the revival of the biotech sector, and the reasons behind renewed attention toward special purpose acquisition companies (SPACs). He also detailed the factors that could establish the foundation for a robust beginning to 2027.
This interview has been edited for length and clarity.
Crunchbase News: How healthy is the IPO market right now?
Bellin: A good IPO year in the U.S. is anywhere from 125 to 175 traditional IPOs, and year to date we’ve seen just south of 90 or so.
The breadth of the market shows me that it’s been a healthy market. We’ve seen industrial products come back to market. We’ve seen tech, consumer markets, energy, utilities and some financial services come back to market.
For the majority of the first three quarters of the year, it was a pretty strong and broad IPO market. But the momentum has halted significantly since September and October.
Is the market in trouble? I would say no. It’s very selective. It’s not shut. Quality issuers with readiness, the right story, the right metrics can still get their deals done.
What has contributed to the slowdown?
Bellin: The macro environment in general was the big mover: rates, inflation, geopolitical concerns. Just that uncertainty was a big factor.
One of the big factors that I’ve seen is valuation. Some fairly aggressive valuations were being asked for in certain transactions, certain offerings, and I think the market — with all those uncertainties that I mentioned — was looking at those valuations and thinking it was maybe a bit rich.
I believe many issuers decided to hit pause and wait for another window to open.
What are public market investors looking for?
Bellin: What investors are really looking for is durable revenue — revenue that’s backed up by strong customers, diverse customers and a growing revenue base. I think it’s that revenue reliability where there is a significant backlog of demand for the product, the services of the IPO issuer. That’s always a strong sign.
The other item is leverage. For companies with significant leverage in a rising-rate environment, the questions are: Can they take on new leverage that creates profitable value opportunities going forward? Can they refinance existing leverage given rates are higher?
Making sure that you’re going into the capital markets with a reasonable leverage ratio, or explaining through your equity story how you’re getting a return on the capital that you have invested from a debt perspective, makes a significant difference.
Is the market open to a broad range of venture-backed startups, or primarily larger companies?
Bellin: Scale matters. Companies that have that scale, whether it’s from a revenue perspective or an asset-based perspective, depending on the sector, make a big difference. Those are the types of companies that can almost dictate the window that they’re going to go out in and do well.
Some of the smaller companies, the midmarket companies, smaller-cap companies — again, outside of life science and biotechs — they’ve been a little bit challenged.
If you’re growing at the right rate, you’re showing the right metrics, the IPO market is fully available to those types of companies. But if you’re still on the lower-scale side of the house, your opportunities may be limited to hit the market.
Will enthusiasm for AI companies carry into public markets, or will investors be more skeptical?
Bellin: I think investors aren’t skeptical of AI; they’re skeptical of spend without visibility — visibility to future earnings, visibility to that revenue durability that I mentioned.
The market is separating AI companies with visible demand from the ones with only a narrative out there, and I think that demand, that growth, the backlog is key.
The other factor we’re seeing in today’s market again comes down to cash generation and profitability. If you’re not profitable, when will that profitable period come? Profitability comes in many different measures. Could be GAAP income, could be EBITDA income, but also cash flows and free cash flows and levered free cash flows that are available to the company.
We haven’t seen a period like this of development, of growth, ever before. It’s exciting, but I do think the market will discern between those companies that are public-company worthy and those that are not.
What does the uneven performance of newly public companies signal?
Bellin: It signals selectivity. There have been some really big winners in the IPO market, and others that, post-issuance, haven’t traded as well as many expected.
Many of the companies that are coming to market have to be very thoughtful on the valuation and what you’re going to go price at. If you’re trying to be too aggressive on pricing, you may trade down post-IPO, which is going to impact those metrics.
Overall, we’re seeing strong candidates come to market. I do think companies are coming to market better prepared now than ever, given this volatility.
What is driving biotech’s resurgence?
Bellin: The M&A market for many of these companies is very strong today. As some of the larger health company names lose the patents to some of the profitable drugs, they’re looking at that next generation of development and where there could be value.
Many of these biotechs were purchased by large pharma companies even before coming to the public markets. That competition for these assets and companies is creating a nice horse trade between an IPO opportunity with a lot of upside and an M&A exit with more certainty day one.
I think M&A is the engine behind the IPO market’s resurgence for these companies.
In the IPO markets, many of these assets have traded very well, and that’s where the momentum and that flywheel effect in the IPO market is very important. We’ve seen that flywheel and that momentum in biotech. We haven’t seen it in the rest of the market in the last couple of months.
Why are SPACs attracting renewed interest?
Bellin: With market volatility, we’re seeing more conversations around SPACs. Because SPACs set valuation certainty on day one, a company looking to exit via SPAC understands the potential cash that may come their way. It’s not certain, of course, given redemptions, etc.
Another factor driving a healthy SPAC market may be these serial SPAC issuers. They understand the SPAC product. They understand what makes a good de-SPAC candidate, and they know whether the target company can be ready, show growth and hit the milestones that may be discussed in the offering document.
The market is healthier and more mature today than in the past. That said, we’re still seeing many SPACs continue to look for a target, given the massive SPAC inventory available to target companies.
What do you expect in 2027?
Bellin: Hundreds of companies are in the pipeline, and they’re ready to go when the market is. Much of the remainder of ’26, and the start of 2027, depends on market momentum.
I’m an eternal optimist. There’s a lot of demand on the buy side; there’s still significant capital available to the right companies. So if we can create that momentum here in the remaining months of 2026, I think we’re going to see a strong start to 2027.
The AI ecosystem that we’ve been talking about is healthy. Demand for energy is always significant, and the right energy companies are coming to market. Consumer and industrial products — those are coming back.
Private equity has been very active in ’26, and I’d expect them to continue that activity in 2027.
I think we’re in for a strong year, but it will remain selective.
Frequently Asked Questions
How healthy is the U.S. IPO market currently?
The U.S. IPO market has recorded just south of 90 traditional offerings year to date, down from a strong start across multiple sectors during the first three quarters due to a momentum slowdown since September and October. However, the market remains open and selective for quality issuers with proper preparation.
What factors are causing the current IPO slowdown?
Broad macroeconomic factors such as interest rates, inflation, and geopolitical concerns have driven uncertainty, while aggressive valuation expectations from certain issuers have caused companies to hit pause.
What are public investors looking for in new IPO candidates?
Investors are prioritizing durable and reliable revenue backed by strong, diverse customer bases and significant backlog demand, alongside reasonable leverage ratios or clear strategies for managing debt in a rising-rate environment.
How are investors evaluating AI companies?
Investors are seeking clear visibility into future earnings and revenue durability rather than spending without backing, separating AI enterprises with verified demand from those relying purely on a narrative.
Why are SPACs experiencing renewed interest?
SPACs offer valuation certainty on day one and involve serial issuers who understand how to identify target companies ready to hit growth milestones, despite ongoing considerations regarding redemptions and available inventory.
Related Crunchbase query:
- Global IPOs For Venture-Backed Companies In 2026
Illustration: Dom Guzman




Comments 0 responses